Thomas A. Bicsak

Synthetic Exendin-4 (Exenatide) Significantly Reduces Postprandial and Fasting Plasma Glucose in Subjects with Type 2 Diabetes

Orville Kolterman, John B. Buse, Mark Fineman et al. · The Journal of Clinical Endocrinology & Metabolism · 2003 · 551 citations · Full text

Effect on Glycemic Control of Exenatide (Synthetic Exendin-4) Additive to Existing Metformin and/or Sulfonylurea Treatment in Patients With Type 2 Diabetes

Mark Fineman, Thomas A. Bicsak, Larry Z. Shen et al. · Diabetes Care · 2003 · 355 citations · Full text

Long‐term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over‐weight metformin‐treated patients with type 2 diabetes mellitus

Robert E. Ratner, David Maggs, Loretta L. Nielsen et al. · Diabetes Obesity and Metabolism · 2006 · 221 citations

Hormonal Regulation of Granulosa Cell Inhibin Biosynthesis*

Thomas A. Bicsak, ERMELINDA M. TUCKER, Scott Cappel et al. · Endocrinology · 1986 · 206 citations

Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial

Scott E. Kasner, Balakumar Swaminathan, Pablo M. Lavados et al. · The Lancet Neurology · 2018 · 177 citations · Full text